



Medicines & Healthcare products Regulatory Agency

Post available for the Review Panel (RP)

The Medicines and Healthcare Products Regulation Agency (MHRA) are seeking to appoint a Clinical pharmacologist to the Review Panel.

The purpose of the Review Panel is to hear representations, in accordance with the legislation, from those who disagree with a decision made by the MHRA. The Review Panel members are greatly appreciated for making their professional expertise available for a public service role that carries out statutory and non-statutory reviews of proposals, decisions and provisional decisions taken by Medicines and Healthcare Products Regulatory Agency.

The Review Panel became a departmental expert committee on 1 November 2012 as a result of the Arm's Length Body (ALB) Review in 2010.

The terms of reference for the Review Panel (MHRA) are to:

- review the provisional determinations made by the Medicines and Healthcare Products Regulatory Agency (MHRA) concerning the classification of a product as a medicine
- perform the role of the 'reviewers' in relation to decisions or proposals made by the MHRA related to the grant, renewal, revocation, suspension, refusal or variation of manufacturer's or wholesale dealing licences, and UK marketing authorisations (the 'persons appointed' role)
- consider any written and/or oral representations made by a person or body notified under regulation 305 of the Regulations that the MHRA are minded to make a determination that that their advertisement is incompatible with the provisions of Part 14 (Advertising) of the Regulations; and/or to advise the Ministers prior to their making a final determination under regulation 306 of the Regulations.

As a member of the Panel, your role is to conduct a review of the decision and after considering all the available information made available by the MHRA and the Applicant during the course of the review period, contribute to the discussions at the Review Panel hearing and to the production of a report with findings, conclusions and any recommendations, with reasons. The Licensing Authority (the MHRA acting on behalf of Health Ministers) must then take the report into account and decide whether to confirm or alter its decision.

The successful candidates will be recognised by their peers as a leader in their field and will have extensive and recent experience in their areas.

Qualities required for the role of Members:

To be considered, you must be able to demonstrate that you have the qualities, skills and experience to meet all the essential criteria for appointment.

Expertise Required

- Clinical pharmacologist

Experience in the following fields: pharmacokinetics, pharmacodynamics, biopharmaceutics, and pharmacokinetic modelling (e.g., population pharmacokinetics or physiologically based pharmacokinetic modelling). Experience to have been acquired within the pharmaceutical industry, governmental departments, clinical practice or academia (please note the requirement in the Declaration of Interest section below).

Up-to-date specialist level of knowledge in one or more relevant scientific areas or broader knowledge across the range of scientific activities in relation to the clinical pharmacology aspects of human medicinal products.

Sound knowledge of relevant legislation and regulatory procedures applicable to the licensing of human medicinal products is desirable.

Essential Criteria:

Successful candidates will:

- be recognised by their peers as a leader in their field. They should have extensive and recent experience in the specified areas.
- have or demonstrate ability to operate effectively on a national expert panel
- be a skilled communicator
- be able to assimilate complex scientific information at short notice and apply this to their expertise in consumer affairs
- be able and prepared to contribute actively to the work of the Review Panel

Desirable Criteria:

Successful candidates will:

- Have an understanding of medicines regulation and be willing to develop this further

Time commitment

A time commitment of approximately 2-3 days per year, based on requests received. Members are entitled to claim an attendance fee of £325 per day.

Location

Meetings will be held primarily virtually or occasionally in London.

Tenure of office

The MHRA determines the length of appointment, which may be up to a maximum of 4 years for one term of appointment (and may be renewed).

Declaration of interest

Chair and members of the Review Panel provide advice direct to the Competent Authority. For this reason, they are not permitted to hold any current personal interests in the pharmaceutical industry. You would be required to make a declaration on appointment that you will dispose of any such interests. These could be your personal and/or financial interests in the pharmaceutical industry; the financial interests of your immediate family in the pharmaceutical industry and any other matter that could affect your impartiality, or that could reasonably be perceived as affecting your impartiality.

Please refer to the Code of Practice for more details: [Code of Practice \(Identifying, declaring and managing interests\)](#)

How to Apply

To make an application please email your CV, completed application form, Declaration of Interests and Monitoring forms to:

CSTRecruitment@mhra.gov.uk - quoting the position and **RP26-3** in the subject field.

If you require an alternative format such as braille, large print or audio please contact the Appointments Team on 020 3080 6060 or CSTRecruitment@mhra.gov.uk, quoting the reference **RP26-3**.

The closing date for applications is Monday 29 June 2026.

The MHRA value and promote diversity and encourage applications from all sections of the community.

[Follow us on social media](#)